Compare FSEA & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSEA | RLYB |
|---|---|---|
| Founded | 1890 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 89.2M |
| IPO Year | 2022 | 2021 |
| Metric | FSEA | RLYB |
|---|---|---|
| Price | $17.17 | $16.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.0K | ★ 11.5K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 6.16 |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.75 |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $11.08 | $0.48 |
| 52 Week High | $17.21 | $17.57 |
| Indicator | FSEA | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 70.87 | 59.20 |
| Support Level | $16.84 | $16.51 |
| Resistance Level | $17.21 | $17.32 |
| Average True Range (ATR) | 0.03 | 0.42 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 93.75 | 73.68 |
First Seacoast Bancorp Inc is the savings and loan holding company. The banks business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one- to four-family residential real estate loans, commercial real estate and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. It operates in single segment of Banking Services.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.